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Abstract: Global deciphering of signal transduction pathways represents a new challenge of the post-genomic era. How-
ever, for the majority of these signaling pathways the role(s), the function(s) and the interaction(s) of the signaling inter-
mediates remain to be characterized in an integrated fashion. The global molecular study of cell signaling pathways and 
networks consequently requires sensitive, robust technologies which may allow in addition multi-parallel and high-
throughput applications. The Alphascreen™ technology, relying on a bead-based homogenous approach, constitutes a 
valuable tool to detect and quantify a wide range of signaling events such as enzymatic activities or biomolecular interac-
tions. In this article, we exhaustively review the literature and report the broad spectrum of Alphascreen™-based applica-
tions in the study of signal transduction pathways. 
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1). INTRODUCTION 
  Intracellular signaling involves a complex network of 
pathways that activate, link and coordinate various functions 
of the cell. The ability of intracellular signaling networks to 
integrate, process and distribute the information through the 
cell requires that individual signaling partners must interact 
with multiple effectors identified as inputs or outputs. In 
addition a significant number of non-proteinaceous entities 
(e.g. lipids, ions, metabolites) also participate in increasing 
the complexity of the above mentioned molecular signaling 
networks. Consequently, it becomes of interest to develop 
specific approaches to monitor, in parallel, a number, as 
large as possible, of events occurring in a homogenous cell 
population and which may reflect the activation of specific 
signaling cascades in precise cellular contexts. 
  The observation that, besides intrinsic enzymatic activi-
ties, proteins exert virtually all of their functions via interac-
tions with other molecules – be they other proteins, nucleic 
acids, lipids, carbohydrates or small molecules – has driven 
the development of technologies to examine these macromo-
lecular associations. The development of large-scale and 
versatile assay formats is therefore needed for monitoring 
enzymatic activities, modifications, interactions or the com-
bination of those parameters for which there are very few 
direct methods available at present. The amplified lumines-
cence proximity homogenous assay is an example of a tech-
nology developed for the biological sciences in the past few 
years that has followed a progression leading to a genomic 
scale use. The Alphascreen™ (AS) technology concept also 
proved to be remarkably malleable, with novel adaptations 
allowing for the detection of protein–DNA, protein–RNA, or 
protein–small molecule interactions, as well as protein–pro-
tein interactions that are dependent or not on post-trans- 
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lational modifications or which occur in different compart-
ments of the cell. Indeed, in the past few years, a large num-
ber of high-throughput assays were developed to decipher 
cellular signaling pathways or to identify compounds that 
may modulate protein-protein interactions or enzymatic ac-
tivities, respectively. Here we review the development of 
functional AS assays which will be providing an integrated 
understanding of cell signaling pathways.  
2). THE ALPHASCREEN™ TECHNOLOGY – HIS-
TORY, PRINCIPLES AND OVERALL DESCRIPTION 
  Originally the technology that led to the development of 
AS, is a luminescent oxygen channeling immunoassay 
(LOCI). LOCI is a homogeneous bead-based immunoassay
 
method capable of rapid, quantitative determination of a 
wide range of
 analytes including high and very low concen-
trations of large and small
 molecules, free (unbound) drugs, 
DNA, and specific IgM. In the mid 1990’s, a group at Syva/ 
Dade Behring developed numerous assays for laboratory 
diagnostics purposes [1, 2]. In 1999 and since then, Perkin- 
Elmer has acquired the exclusive rights to develop the LOCI 
technology for research and drug screening applications. The 
novel trademarked technology named AlphaScreen™ was 
born. Since 1999, new homogenous assays appeared to 
measure several aspects of the expression/activation of sig-
nal transduction molecules, enzymatic activities, to screen 
for compounds or to quantify specific biomarkers (Fig. 1). 
  These assays derived from LOCI technology, use latex
 
particle pairs which are formed in the assays through specific 
binding
  interactions by sequentially combining the sample 
and two reagents. One
  particle contains a photosensitizer 
whereas the other contains a chemiluminescer.
  Irradiation 
causes the photosensitized formation of singlet oxygen spe-
cies in the photosensitizer-containing bead. The singlet oxy-
gen species transfer to a bound particle and activates the 
chemiluminescer, thereby
 initiating a delayed luminescence 
emission. The singlet oxygen species display a lifetime of 94    Current Genomics, 2009, Vol. 10, No. 2  Taouji et al. 
approximately 4 s which allows them to travel 200 nm in 
aqueous solutions. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of the Alphascreen™ technology 
development time-line (gray arrow) placed in parallel to the related 
published papers (n=46). 
  Based on these principles, the AS technology has been 
developed in which Donor (photosensitizer) and Acceptor 
(chemiluminescer) microbeads can be coated with target-
specific antibodies, secondary antibodies, proteins, or any 
molecular entity of interest. A signal is produced when the 
AS Acceptor and Donor beads are brought into proximity 
(<200 nm) by a molecular interaction occurring between the 
binding partners captured on the beads. Laser excitation of 
the Donor beads at 680 nm causes ambient oxygen to be 
converted to the singlet state by photosensitizers (phthalo-
cyanine). These react with chemiluminescent agents (thiox-
ene, anthracene, rubrene) within the Acceptor bead only 
when the latter is in close proximity (Fig. 2). Upon energy 
transfer between those compounds, activated rubrene emits 
light at 520-620 nm which is in turn detected by the photo-
detector in a microplate reader. An excitation wavelength 
higher than the emission wavelength ensures a low assay 
fluorescent background by avoiding any auto-fluorescence 
from biological media or compounds. However, AS may be 
sensitive to other types of interferences. Antioxidants or 
other quenchers of reactive oxygen species like metal ions 
can strongly affect the emitted signal. Moreover, since the 
AS detection is only based on a fluorescence-intensity meas-
urement, colored compounds absorbing in the 500–600 nm 
wavelength range artificially decrease the AS signal and 
therefore may be detected as false positives in HTS. To cir-
cumvent these limitations, Acceptors beads were modified to 
contain Europium. Europium (Eu) has a long fluorescent 
lifetime, longer than several hundreds of microseconds, 
whereas traditional organic reagents have several nanosec-
onds; the emission peaks of Eu complexes are 615 nm and 
the fluorescent peak profiles are sharp: the half-widths are 10 
nm – 20 nm. It is known that the fluorescence is based on the 
energy transfer from the ligand to the central metal ion. The 
characteristics of these new beads allowed for the develop-
ment of a novel assay format commercialized as AlphaL-
ISA™. Using such fluorescent properties this assay leads to 
the reduction of background interferences of short lifetime 
from the sample matrix, and enables highly sensitive detec-
tion and thus leads to greatly increased specificity and sensi-
tivity of the assay.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Principles of Alphascreen™. 
AlphaScreen is a bead-based non-radioactive and homogeneous 
detection technology. Donor and Acceptor microbeads can be 
coated with target-specific antibody, proteins, or secondary reagents 
(streptavidin, glutathione, Nickel). A signal is produced when the 
AlphaScreen Acceptor and Donor beads are brought into proxim-
ity by a molecular interaction occurring between the binding part-
ners captured on the beads. Laser excitation at 680 nm causes am-
bient oxygen to be converted to the singlet state by photosensitizers 
on the Donor bead. These react with chemiluminescent agents on 
the Acceptor bead only when the latter is in close proximity, emit-
ting light at 520-620 nm. AlphaScreen allows one to quantify 
various analytes by performing competition assays and interpolat-
ing signals with a standard curve.  
3). HOW DOES AS CONTRIBUTE TO DECIPHERING 
CELL SIGNALING PATHWAYS? 
  In the following sections, we will extensively review the 
literature and explore the use of AS as a tool to explore cell 
signaling pathways. The scheme of our analysis is shown on 
Fig. (3). Briefly, we will describe the AS-based assays moni-
toring the interaction between receptors and their respective 
ligands, then those aiming at evaluating the activation of 
specific signaling pathways by measuring the intracellular 
concentrations of second messengers, enzymatic activities, 
or specific sub-cellular localization and finally the assays 
which aim at measuring the occurrence of specific post-
translational modifications whose role could be involved in 
various aspects of cell signaling. 
a). Receptor-Ligand Interactions 
i). G Protein-Coupled Receptors  
  Thus far, only two types of assays have been developed 
to evaluate receptor-ligand interactions. The first type of 
assay aims at characterizing the human GPR3, GPR6 and 
GPR12 receptors which belong to the GPCR superfamily. 
These proteins exhibit high similarity to each other. Devoid 
of any identified natural ligand, these receptors are currently 
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their activation process, various functional AS-based assays 
(cAMP AS assays, mobilization of intracellular Ca
2+, ago-
nist-induced internalization) were applied to demonstrate 
that Sphingosine 1-phosphate (S1P) and dihydrosphingosine 
1-phosphate (DHS1P) were bona fide activators of the 
GPR3, GPR6 and GPR12 family [4]. Lysophosphatidic acid 
(LPA, 1-acyl-2-sn-glycerol-3-phosphate) signaling through 
G proteins
 mediates a variety of biological functions includ-
ing cell proliferation,
 cell survival, cytoskeleton remodeling, 
cell migration, and
 alterations in differentiation [5, 6].  
  Five LPA-specific GPCRs have thus far been identified, 
termed
  LPA1–5 [7-9]. LPA4,  also known as GPR23, is the 
only receptor that has
 yet to receive independent confirma-
tion as a bona fide LPA receptor
 since its initial report [9]. 
This putative LPA receptor particularly stands out owing to
 
its relatively low predicted amino acid sequence
 homology 
compared with the well studied LPA1–3, a Kd  45
  nM for 
LPA, and an ability to mobilize calcium and increase
 cAMP 
production. Recently, Lee and colleagues confirmed the 
finding that GPR23
 is indeed a biologically relevant receptor 
for LPA and report
 several novel aspects of LPA4 signaling 
that extend its functional
 roles [8].  
ii). TNFalpha Receptor  
  Wilson and colleagues developed an AS-based high-
throughput assay to monitor ligand binding to a member of 
the tumor necrosis factor (TNF) receptor superfamily [10]. 
The binding affinity of the extracellular domain of the OX40 
receptor (fused to the constant domains of human IgG) to the 
OX40 ligand was determined. In addition, using the same 
approach small peptides capable of inhibiting the OX40 re-
ceptor:ligand interaction were also identified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Schematic representation of a canonical signaling pathway “from the plasma membrane to the nucleus”. 
The receptor-ligand interaction occurring in the extracellular space leads to the activation of the membrane receptor which transduces a sig-
nal into the cytoplasm. At this stage, signaling can involve post-translational modifications of proteins (PTM), formation of complexes (scaf-
folds), modification of lipids and enzyme cascade activation (GTPases, kinases). Activated complexes can then translocate in the nucleus 
where transcriptional activation processes can take place, followed by mRNA maturation, expression and translation into active proteins. 96    Current Genomics, 2009, Vol. 10, No. 2  Taouji et al. 
b). Studying GPCR-Dependent Signal Transduction 
Pathways 
  The signaling pathways which have been the most stud-
ied using AS are those downstream of GPCR activation. The 
GPCR superfamily constitutes a large group of membrane 
receptors known to modulate a wide range of biological re-
sponses, including cell growth, differentiation, migration, 
and inflammatory processes [11]. The initial stage of GPCR 
activation occurs via agonist-induced conformational chan- 
ges in the receptor to form an active agonist–receptor com-
plex that is able to interact with heterotrimeric G-proteins 
and facilitate its activation via exchange of GDP for GTP at 
the -subunit. All known effectors are regulated by the dis-
sociated  or  subunits and not by the heterotrimer. Effec-
tors include mainly enzymes such as adenylyl cyclases, phos- 
pholipases, phosphodiesterases, or kinases and ion channels. 
i). Monitoring cAMP Levels 
  Production of cAMP is controlled through the adenylyl 
cyclase family of enzymes, which convert adenosine tri- 
phosphate (ATP) to cAMP and inorganic pyrophosphate. 
These enzymes are activated or inhibited via direct interac-
tion with G protein -subunits and, for some isoforms, with 
Ca
2+ and calmodulin. Following Gs-coupled GPCR activa-
tion, active Gs molecules exert a positive effect on adenylyl 
cyclase catalysis; cAMP is produced and is then able to bind 
to protein kinases within the cell leading to the regulation of 
target enzymes and transcription factors [12, 13]. 
  Changes in the levels of intracellular cAMP can be 
measured directly through competition of antibody-captured 
labelled cAMP, with demonstrated assay-specific limitations 
[14, 15]. An alternative high-throughput homogeneous plat-
form assay has been developed for screening GPCRs which 
is based on the measurement of intracellular cAMP concen-
trations [15-19]. Gabriel and colleagues reported a direct 
comparison of AlphaScreen™, HTRF, HitHunter™ and FP 
cAMP assay platforms and suggest the use of AS or HTRF 
for cells expressing low levels of GPCRs owing to higher 
sensitivities [14]. As an example, parathyroid hormone 
(PTH), a major regulator of bone remodeling and calcium 
ion homeostasis, exerts its effects by binding and activating 
the GPCR superfamily member PTH/PTH-related peptide 
receptor (PPR). Carter and Schipani showed that a modified 
synthetic peptide (SW106) equivalent to PTH fragment (1–
34) had PPR antagonistic effects determined using AS [20]. 
The ability of SW106 to block PTH-initiated cAMP accumu-
lation was shown to be specific to its actions on the PPR and 
not related to its ability to interfere with other signaling 
mechanisms. 
c). Monitoring Lipid Signaling 
  Many cellular responses elicited by GPCRs are mediated 
by phospholipid signaling cascades, initiated by G and G 
subunits of heterotrimeric G proteins. The hydrolysis of 
membrane phospholipids leads to the formation of various 
bioactive lipid mediators acting either as extracellular signal-
ing molecules or as intracellular second messengers. 
  A crucial second messenger-generating system is the 
stimulation of phosphoinositide-specific  phospholipase C 
(PLC) isoforms. Upon activation, PLC enzymes hydrolyze 
phosphatidylinositol-4,5-bisphosphate (PIP2) at the inner 
face of the plasma membrane and thereby generate the mes-
sengers, diacylglycerol (DAG) and inositol-1,4,5-trisphos- 
phate (IP3). 
i). PI-3 Kinase 
  Gray and colleagues [21], using suitably tagged pleck-
strin homology (PH) domains as probe and the AS technol-
ogy or time-resolved FRET, quantified phosphoinositides in 
cell extracts. DAG and IP3 signaling molecules led to the 
activation of several protein kinase C (PKC) isoforms and 
the release of calcium from intracellular stores, respectively 
[21]. 
  Phosphoinositide 3-kinases (PI3Ks) represent a family of 
dual specificity enzymes that can act as lipid and protein 
kinases to regulate numerous biological processes including 
cell growth, differentiation, survival, proliferation, migration 
and metabolism [22, 23]. The lipid kinase activity of PI3K 
catalyzes the addition of a phosphate group at the D-3 posi-
tion of phosphatidylinositol lipids, generating different 3' 
phosphorylated products that act as second messengers [24].  
   The regulatory subunit of PI3Ks – p85 – harbors a p110-
binding region flanked by two SH2 (Src Homology 2) do-
mains, which are pivotal in mediating the activation of class 
IA PI3Ks by receptor tyrosine kinases (RTK). Indeed, SH2 
domains of the p85 protein specifically bind to phosphoty-
rosine residues in the YXXM motif on the cytosolic tails of 
receptor tyrosine kinases or other membrane-associated pro-
teins, eventually docking the holoenzyme adjacent to the 
plasma membrane phospholipid bilayer, where its lipid sub-
strates reside [23]. Moreover, the PI3K catalytic subunit 
p110 harbors the ability to be synergistically triggered by 
both G proteins and phosphotyrosyl peptides and might thus 
function by integrating signals from both GPCR- and RTK-
signaling cascades.  
  Different types of phosphatidylinositol 3-phosphates can 
be generated by PI3Ks. In vivo, class I kinases predomi-
nantly produce PtdIns(3,4,5)P3 from PtdIns(4,5)P2, while 
class II and III enzymes mainly convert PtdIns to PtdIns(3)P. 
PtdIns(3,4,5)P3 exerts its second messenger function by re-
cruiting and activating a wide array of proteins harboring a 
PH domain (PDK1, PLC, GEFs and GAPs), which in turn 
initiate numerous intracellular responses. PH domains repre-
sent the best characterized elements binding PIP2 and PIP3. 
They exist as a large consensus sequence domain family that 
includes diverse members differing in their ability to bind to 
distinct phosphoinositides; whereas the PH domain found in 
PKB/AKT, BTK, and PDK1 recognize PtdIns (3,4,5)P3 with 
high affinity and specificity, others such as those found in 
PLC, TAPP1 and TAPP2 interact exclusively with PtdIns- 
(4,5)P2 [25]. Among the PH domain-containing proteins 
activated by PtdIns(3,4,5)P3, of particular interest are phos- 
phoinositide-dependent kinase 1 (PDK1) and the serine/thr- 
eonine kinase PKB/AKT [26], both integral components of 
key cellular signaling pathways. 
  A novel approach to quantitation of phosphoinositides in 
cell extracts and in in vitro enzyme-catalyzed reactions has 
been described and consists in using labeled pleckstrin ho-
mology (PH) domain probes [21]. PtdIns(3,4,5)P3 present in 
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lated with platelet-derived growth factor or with the bacteri-
ally-derived peptide fMLP (formyl-methionyl-leucyl-phenyl- 
alanine), respectively, was shown to be detectable at pico-
mole sensitivity; stable complexes were generated between 
the biotinylated target lipid and the appropriate PH domain, 
and phosphoinositides present in samples were detected by 
their ability to compete for binding to the PH domain. Com-
plexes were detected using AS technology or time-resolved 
FRET. Interestingly, the elevated flexibility of this assay 
platform was evaluated by swapping GRP1 and TAPP1 PH 
domains which respectively bind exclusively to PIP3 and 
PIP2. 
  PDK1-mediated activation of AKT, the key effector of 
class I PI3K signaling, results in modulation of distinct sig-
naling cascades regulating cell proliferation (GSK3, FOXO), 
survival (BAD, MDM2) and protein synthesis/cell growth 
(TSC, RHEB, mTOR). One example of the above-mentioned 
PH domain competition approach is the development of a kit 
that would monitor the presence of the phosphoinositide 
PIP3, a second messenger in the activation pathway of AKT 
kinase; upon activation of PI3-kinase, PIP3 is produced 
which activates PDK1. PDK1, in turn, activates AKT by 
phosphorylation at the Thr308 residue. Consequently, the 
level of PIP3 would directly reflect PI3K activity and poten-
tially link it to the activation level of AKT. 
d). GTPase Signaling 
  The superfamily of small GTPases constitutes an essen- 
tial component of the signaling pathways that link extra- 
cellular signals via transmembrane receptors to cytoplasmic 
or nuclear responses. The Ras-superfamily of small GTPases 
and their G-protein cousins act by a conserved mechanism: 
the molecules' signaling activities differ when bound to GTP 
versus GDP, and their GTPase activity (GTP hydrolysis to 
GDP) determines their GTP-bound versus GDP-bound state. 
In the development of a new assay allowing the systematic 
comparison of the biochemical properties of monomeric 
GTPases of the Ras superfamily. Caruso and colleagues used 
two high-throughput methods, AS and FlashPlate
®, to meas-
ure nucleotide binding capacity, nucleotide exchange, and 
GTP hydrolysis activities of small monomeric GTPases; 
integration of the results from this study led to the proposal 
of a novel classification of Rho GTPases based on their en-
zymatic activities [27].  
e). Monitoring Protein Kinase Activity 
  The emergence of technologies allowing high-through- 
put, system-wide experiments has provided a detailed and 
objective view of downstream transcriptional changes fol-
lowing various cellular stimuli. However, many critical 
events involved in cellular responses are mediated by 
changes in post-translational protein modifications rather 
than transcriptional changes. It is well established that pro-
tein modifications can influence and control enzymatic activ-
ity, protein conformation, protein:protein interactions, and 
cellular localization. Even for protein phosphorylation, 
which affects an estimated one-third of all proteins and is the 
most widely studied post-translational modification [28], 
only a small subset of total in vivo phosphorylation sites has 
been discovered so far [29]. 
  Protein kinases represent one of the most important 
classes of therapeutic targets in high-throughput drug screen-
ing. Tyrosine kinases and serine/threonine kinases are known 
to play key roles in signal transduction as well as in cell 
growth and differentiation. Recently, homogeneous protein 
kinase assays including fluorescence resonance transfer as-
says (FRET) [30], fluorescence polarization assays and AS 
assays [31-35], ATP consumption assays and superquench-
ing assays [36] have been developed for the HTS of kinase 
activity. Indeed, the use of such assays in HTS, and probably 
a combination of them, may allow the detection of a broader 
spectrum of inhibitors presenting higher specificities. 
i). JNK Signaling 
 The  c-Jun N-terminal protein kinases (JNK) are encoded 
by three genes: while Jnk1 and Jnk2 genes are expressed 
ubiquitously, Jnk3 has a more limited pattern of expression 
and is largely restricted to brain, heart, and testis. Remarka-
bly, these genes are alternatively spliced to create ten JNK 
isoforms which, together with ERK and p38
MAPK, are impli-
cated in various MAP kinase-dependent pathways. The JNK 
pathway has been implicated in both apoptosis and survival 
signaling, and is activated by exposure of cells to stress 
stimuli (e.g. UV). To model ocular diseases of the retina 
(such as ESCS (Enhanced S-Cone) syndrome) and photore-
ceptor degeneration (RPE65
-/-), RPE (retinal pigment epithe-
lium) cells were exposed to UV irradiation, and JNK protein 
expression was monitored by an AS-based assay [37]. The 
activation (phosphorylation) of JNK kinases (1, 2, 3) upon 
varying treatment doses and duration of UV irradiation was 
observed. The activator protein-1 (AP-1) was itself activated 
through phosphorylation of c-Jun and c-Fos, induced by JNK 
and p38, respectively. Moreover using various isoforms of 
JNK inhibitory peptides (long, short and D- forms; JNKi) it 
seems that UV-induced JNK activation reduced pro-survival 
effects of ERK2 which was reversed by pre-incubation with 
the JNKi peptide (retro-inverso peptide). Using the same 
luminescence-based approach Guenat and colleagues identi-
fied a peptide inhibitor and characterized its mechanism of 
action by measuring its binding affinity for endogenous JNK 
[31]. 
ii). JAK Signaling 
  The family of signal transducers and activators of tran-
scription (STATs) consists of seven transcription factors that 
respond to a variety of cytokines, hormones, and growth 
factors. STATs are activated by tyrosine phosphorylation, 
which results in their dimerization and translocation into the 
nucleus where they exert their effect on transcription of regu-
lated target genes. The phosphorylation of STATs is medi-
ated mainly by Janus kinases (JAKs), one of ten recognized 
families of non-receptor tyrosine kinases. Mammals have 
four members of this family, JAK1, JAK2, JAK3 and Tyro-
sine kinase 2 (TYK2).  
  The JAK/STAT pathway plays a critical role in hema-
topoietic and immune cell function. In particular, STAT5 is 
phosphorylated by several JAKs, including Jak3, JAK2, and 
TYK2, in response to interleukin-2, erythropoietin (EPO), 
and interleukin-22, respectively. Using the SureFire pSTAT5 
assay that utilizes AS, Binderand and colleagues evaluated 
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cessfully completed a small-scale screening campaign to 
identify inhibitors of this biological event [38]. 
  In addition, the suppressor of cytokine signaling (SOCS) 
which is involved in the negative regulation of the cytokine-
induced JAK/STAT pathway was studied using AS [39]. In 
order to decipher whether SOCS2 is a major negative regula-
tor of GH action, Greenhalgh et al., (2005), using SPR tech-
nology, characterized the interaction between SOCS2 and 
the GH receptor and found that SOCS2 binds to 2 phos-
phorylated tyrosines on the GH receptor. An AS-based inter-
action assay indicated that phosphorylated Tyr595 and 
Tyr487 peptides derived from the GH receptor were able to 
bind to the SOCS2 SH2 domain, which was confirmed in 
vivo by their ability to stimulate the STAT5 pathway [40]. 
iii). ERK Signaling 
  Detection of the activation of ERK1/2 in Gq-coupled 
GPCR systems was demonstrated using AS-based method-
ologies and led to comparable pharmacological data for re-
ceptor agonist and antagonist data obtained using GPCR 
activation measurement techniques [41]; whether amino ac-
ids mediate the activation of ERK1/2 is nevertheless still 
poorly documented. Lee and colleagues examined the effect 
of L-amino acids on Ca
2+-stimulated ERK1/2 phosphoryla-
tion by Western blotting and the SureFire AS-based phos-
phorylated ERK1/2 assay [8]. By both these methodologies, 
these authors demonstrate that certain amino acids allosteri-
cally activate extracellular Ca
2+-stimulated ERK1/2 phos-
phorylation in Ca
2+ sensing Receptor expressing HEK-293 
cells [8]. 
f). Other Types of Signaling-Related Information 
i). Monitoring Nuclear Localization 
  An important feature in the completion of signaling 
pathways from the plasma membrane to the nucleus is the 
nuclear translocation steps, which brings in contact genomic 
DNA and potential regulators of its expression, structure etc 
(Fig. 3). This occurs when cargo molecules containing spe-
cific nuclear localization sequences (NLS) bind to karyo-
pherins, such as importin- and importin-, to form com-
plexes (importin-/importin-/cargo) that are transported 
into the nucleus through interactions with nucleoporins in the 
nuclear pore complex NPC. Hearps and Jans reported that 
the integrase, known to be also involved in the nuclear im-
port of HIV DNA, exhibits a high affinity interaction with 
importin- and with the heterodimer / [42]. Similarly, 
using an AS-based assay and recombinant Hisx6 and biotin-
tagged proteins, Walgstaff and Jans determined the high af-
finity of the importin-/ heterodimer to the NLS-containing 
protein of SV40 T antigen and HIV integrase. A similar as-
say was performed to define flanking residues implicated in 
the modulation of the IMP-NLS interaction [43]. In a recent 
paper, Bartholomeeusen and colleagues verified the specific 
interaction between JPO2 and LEDGF/p75 by pull-down, 
AS [44], which was also confirmed by co-immunoprecipita- 
tion [45]. Moreover, in AS competition assays, the HIV-1 
integrase showed a mutually exclusive binding to either 
JPO2 or LEDGF/p75. However, differing mechanisms of 
binding were suggested by continuing interaction of JPO2 
with some LEDGF/p75 mutants that are totally defective for 
interaction with HIV-1 integrase [46,47]. In another study, 
Al Mawsawi and colleagues observed an inhibitory effect of 
the LEDGF peptide on the LEDGF/P75-interaction (his6-
tagged integrase and flag-LEDGF/P75) [48]. 
ii). Nuclear Receptors 
  Nuclear receptors are known to function as multimeric 
structures and generally show a large spectrum of ligands. In 
this section, we will illustrate how the AS technology was 
used to monitor the functionality of four different nuclear 
receptors. The first example is provided by the constitutive 
androstane receptor (CAR; NR1I3) which is an orphan nu-
clear receptor that is predominantly expressed in the liver 
[49, 50]. CAR and Pregnane X receptor (PXR) share a 
highly conserved DNA binding domain (DBD). Both recep-
tors bind to DNA as a heterodimeric complex with RXR, 
which binds to the vitamin A metabolite 9-cis- retinoic acid 
(9cRA). In addition to CAR and PXR, RXR also serves as an 
obligate heterodimeric partner for about fifteen other nuclear 
receptors including receptors for retinoic acid (RAR), thy-
roid hormone (TR), vitamin D (VDR), and fatty acids 
(PPARs). Binding of the TIF2 (transcription intermediary 
factors member of the p160 family of nuclear receptor coac-
tivators) motif and ligands to CAR or CAR/RXR heterodi-
mers were determined using AS. These experiments were 
conducted with Ligand Binding Domain receptor and bi-
otinylated TIF2 peptide, the IC50 was determined for the 
CAR activator TCPOBOP (1,4 bis[2-(3,5-dichloropyridyl- 
oxy)]benzene) and androstanol [51]. 
  The functional interaction between the orphan nuclear 
receptors, small heterodimer partner (SHP) and liver receptor 
homolog 1 (LRH-1), where SHP binds to LRH-1 and re-
presses its constitutive transcriptional activity, is crucial for 
regulating genes involved in cholesterol homeostasis. Li and 
colleagues reported structural and biochemical analyses of 
the LRH-1-SHP interaction, and the binding of the cofactor 
motifs to the nuclear receptors was determined using AS 
[32]. They demonstrated that only the second SHP LXXLL 
motif is required for repressing LRH-1, and that this motif 
displays a strong preference for binding to LRH-1 over the 
closely related receptor steroidogeneic factor 1 (SF-1). 
  Finally,  the herbicide Atrazine (ATR) binds directly to 
SF-1 and induces the cAMP phosphodiesterase (PDE) 4D, 
which is expressed in human fetal tissues and is proposed to 
mediate inflammatory responses in the myometrium. ATR 
response seems to be mediated via convergence of NR5A 
(nuclear receptor family) activity and cAMP signaling, to 
potentially disrupt normal endocrine development and func-
tion. Using cellular and biochemical assays several lines of 
evidence suggest that ATR might not function by directly 
binding to NR5A receptors and failed neither to alter coacti-
vator peptide recruitment using an AS assay nor to displace 
the bacterial phosphatidyl glycerol or an exchanged PIP3 
ligand present in the SF-1 ligand binding pocket [52]. ATR 
also activates PI3K signaling as evidenced by the increase in 
phosphorylation of AKT or protein kinase B.  
iii). Protein Metabolism 
  The best example of protein modification, characteriza-
tion and enzyme substrate interaction was reported previ-
ously [53]. In this study, the authors attempted to identify 
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protein ligase RSP5. Using AS to detect ubiquitination in 
vitro, the authors screened hundreds of purified yeast pro-
teins for ubiquitination, and identified previously reported 
and novel substrates of the yeast E3 ligase RSP5. The rele-
vance of these substrates was confirmed in vivo by showing 
that a number of them interact genetically with Rsp5, and 
some were ubiquitinated by RSP5 in vivo.  
4). PERTURBING SIGNALING PATHWAYS 
  This section aims at reviewing all the AS-based ap-
proaches that successfully identified compounds, small 
molecules, or peptides whose biological activity was to per-
turb specific signaling pathways. On the one hand, we will 
review the literature available and on the other hand describe 
the results available in public repositories. 
a). Literature Review 
  Several examples of the use of AS in the identification of 
signaling pathway modulators are available in the literature. 
The first type of assays which was used to identify such 
molecules was based on monitoring the activation levels of 
second messengers downstream of membrane receptors in 
response to agonists or antagonists. This is illustrated for 
instance by the Human formyl peptide-receptor-like-1 
(FPRL-1) which is a promiscuous G protein-coupled recep-
tor (GPCR), and belongs to a chemo-attractant receptor fam-
ily protein. The FPRL-1 mediated release of cAMP was 
measured using AS. To stimulate cAMP production, fors- 
kolin was added at 10 μM (final concentration) to HEK293 
cells. The concentrations of ligands tested were 10 pM to 
200 nM for chemokines, 1 pM to 20 nM for W-peptide and 
0.5 nM to 10 μM for other compounds and a potent agonist 
of FPRL-1 was identified as being a truncated form of 
CKbeta8-1 [54]. Similarly, Uhlenbrock and colleagues [4] 
discovered GPCR activators (sphingophospholipids) and 
Bley and colleagues reported the characterization of structur-
ally distinct, potent and selective IP (prostacyclin) receptor 
antagonists using the same type of assay [55]. 
  The second type of assays developed to identify agents 
perturbing signaling pathways is based on the evaluation of 
altered protein-protein interactions. This was illustrated for 
the study of Hepatocyte Growth Factor receptors. Indeed as 
receptor dimerization is a general paradigm for activation of 
RTKs, Tolbert et al. (2007) exploited AS technology to 
evaluate binding affinity of human NK1, a natural variant of 
hepatocyte growth factor (HGF), to Met receptor tyrosine 
kinase [56]. The results suggested that NK1 was capable of 
binding and inducing Met dimerization in a heparin-
dependent manner which was confirmed in vivo. Similarly 
and at a more general level, the use of the AS technology 
was proposed to study the concept of altered protein-protein 
interactions in the identification of perturbing agents. Indeed 
as protein-protein interactions allow the recruitment of cyto-
plasmic polypeptides to activated receptors, direct their as-
sembly into larger complexes, target them to defined sub-
cellular locations, and determine the specificity with which 
enzymes interact with their substrates, they consequently 
represent targets of choice to be perturbed [57]. 
b). Public Repositories 
  In addition to the published data mentioned in the previ-
ous section, a repository of the AS-based results obtained in 
the screening of compound libraries is available at NCBI 
(http://www.ncbi.nlm.nih.gov/) in the PubChem Bioassay 
database [58] which contains bioactivity screens of chemical 
substances described in PubChem Substance. It provides 
searchable descriptions of each bioassay, including descrip-
tions of the conditions and readouts specific to that screening 
procedure. At present, eight AS-based screens are reported 
which aim at identifying inhibitors of Her-Kinase Expression 
(AID: 461, AID: 742, AID: 645, AID: 814), inhibitors of 
ERK1 signaling (AID: 995), inhibitors of JNK3 signaling 
(AID: 530), and finally disruptors of Hsp90 Co-chaperone 
interaction (AID: 632, AID: 595). 
5). CONCLUSIONS AND PERSPECTIVES 
  In the above sections, we have described how AS was 
use to monitor, dissect and perturb the molecular mecha-
nisms playing a role in the activation of specific signaling 
pathways. 
  It is clear that each component of a given signaling path-
way could be analyzed individually at the genome scale (for 
instance analyzing kinomes, interactomes, etc.) however the 
integrated representation of a number of signaling pathways 
activated in response to specific stimuli would definitely 
provide a better understanding of the molecular mechanisms 
set in place in the cell to respond. 
  Moreover, it is interesting that most of the signaling steps 
described in Fig. (3) were evaluated using a unique techno-
logical approach as AS. This most likely reflects the high 
versatility of the technology. In addition, although most of 
the assays described in this review have demonstrated ex-
perimental robustness, sensitivity, and efficiency, they were 
carried out separately and despite of the objectives of provid-
ing a complete and integrated view of the signaling pathways 
activated in response to given stimuli. 
  Currently, with the increasing needs from both industry 
and academia to evaluate the global impact of various chal-
lenges on cells signaling pathways, it is easy to anticipate 
that integrated platforms allowing for global (and as exhaus-
tive as possible) analyses of signal transduction pathways in 
parallel and in formats compatible with high-throughput 
screening will emerge. 
  The establishment of such tools will be of course facili-
tated by the use of a single technology adaptable to the 
evaluation of an almost infinite number of parameters. In this 
context, the problematic would necessarily locate beyond the 
development of the assays, but rather at the level of the in-
terpretation, integration and visualization of the quantitative 
data. 
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